FDA
-
-
-
-
-
-
-
Leading Independent Proxy Advisory Firms Recommend Ritter Pharmaceuticals Shareholders Vote in Favor of its Merger and Each of the Merger Proposals
-
-
-
-
-
-
-
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
-
-
-
-
-
-
-
Ritter Pharmaceuticals Hosts Conference Call on August 7, 2019 to Highlight Recent Lactose Intolerance Market Research Findings
-
-
-
-
-
-
-
Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance
-
-
-
-
-
-
-
Ritter Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019
-
-
-
-
-
-
-
Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
-
-
-
-
-
-
-
Ritter Pharma (RTTR) Reports Over 50% Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

